Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Immune Landscape of Renal Cell Carcinoma
share announcement

Immune Landscape of Renal Cell Carcinoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 2004

Special Issue Editors

Dr. Scott S. Tykodi

E-Mail Website
Guest Editor
University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Interests: kidney cancer; clinical trials; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Dr. Yuexin Xu

E-Mail Website
Guest Editor
University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Interests: renal cell carcinoma; T cell immunity; tumor-associated T cell receptor repertoires; bioinformatic approaches to characterizing T cell receptor specificity

Special Issue Information

Dear Colleagues,

This Special Issue, entitled “Immune Landscape of Renal Cell Carcinoma”, recognizes the unique history of renal cell carcinoma (RCC) as a solid tumor responsive to immune-based treatments. Immune checkpoint inhibitors (ICIs) are now firmly established as part of front-line treatment regimens for advanced disease and associated with improved response rates, durability of disease control, and overall survival. Yet, despite these important gains, clinical outcomes remain heterogenous. Primary or acquired treatment resistance is observed in most patients, with the predominant result being that metastatic disease remains largely incurable.

The aim of this Special Issue is to broadly address both the advantages and disadvantages of ICIs and other immune-based therapies for advanced RCC, exploring clinical outcomes derived from the use of standard-of-care and novel emerging immunotherapy agents and combinations; translational studies including biomarker discovery, tumor antigen identification, and the investigation of mechanisms for tumor resistance and escape; and the preclinical modeling of RCC-directed immunotherapy.

For this Special Issue, we welcome the submission of review papers and original research articles.

We look forward to receiving your contributions.

Dr. Scott S. Tykodi
Dr. Yuexin Xu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renal cell carcinoma
  • solid tumor
  • immunotherapy
  • immune checkpoint inhibitor
  • T cell
  • tumor microenvironment
  • biomarkers
  • tumor antigen
  • immune surveillance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

36 pages, 1669 KiB  
Review
Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas
by Justin W. Miller, Jeffrey S. Johnson, Christopher Guske, Gowtam Mannam, Firas Hatoum, Michelle Nassar, Marine Potez, Adnan Fazili, Philippe E. Spiess and Jad Chahoud
Cancers 2025, 17(2), 326; https://doi.org/10.3390/cancers17020326 - 20 Jan 2025
Viewed by 987
Abstract
Renal cell carcinoma (RCC) is a heterogeneous disease that represents the most common type of kidney cancer. The classification of RCC is primarily based on distinct morphological and molecular characteristics, with two broad categories: clear cell RCC (ccRCC) and non-clear cell RCC (nccRCC). [...] Read more.
Renal cell carcinoma (RCC) is a heterogeneous disease that represents the most common type of kidney cancer. The classification of RCC is primarily based on distinct morphological and molecular characteristics, with two broad categories: clear cell RCC (ccRCC) and non-clear cell RCC (nccRCC). Clear cell RCC is the predominant subtype, representing about 70–80% of all RCC cases, while non-clear cell subtypes collectively make up the remaining 20–30%. Non-clear cell RCC encompasses many histopathological variants, each with unique biological and clinical characteristics. Additionally, any RCC subtype can undergo sarcomatoid dedifferentiation, which is associated with poor prognosis and rapid disease progression. Recent advances in molecular profiling have also led to the identification of molecularly defined variants, further highlighting the complexity of this disease. While immunotherapy has shown efficacy in some RCC variants and subpopulations, significant gaps remain in the treatment of rare subtypes. This review explores the outcomes of immunotherapy across RCC subtypes, including rare variants, and highlights opportunities for improving care through novel therapies, biomarker-driven approaches, and inclusive clinical trial designs. Full article
(This article belongs to the Special Issue Immune Landscape of Renal Cell Carcinoma)
►▼ Show Figures

Figure 1

14 pages, 498 KiB  
Review
A Review of Neoadjuvant Therapy for Localized and Locally Advanced Renal Cell Carcinoma
by Qian Qin, Isamu Tachibana, Vitaly Margulis, Jeffrey A. Cadeddu and Tian Zhang
Cancers 2025, 17(2), 312; https://doi.org/10.3390/cancers17020312 - 19 Jan 2025
Viewed by 632
Abstract
The introduction of vascular endothelial growth factor receptor-tyrosine kinases (VEGFR-TKIs) and immune checkpoint inhibitors (IOs) have drastically altered the treatment landscape for kidney cancer, with doublet combination immunotherapy (IO/IO or IO/VEGFR-TKI) now set as the standard front-line treatment for advanced renal cell carcinoma [...] Read more.
The introduction of vascular endothelial growth factor receptor-tyrosine kinases (VEGFR-TKIs) and immune checkpoint inhibitors (IOs) have drastically altered the treatment landscape for kidney cancer, with doublet combination immunotherapy (IO/IO or IO/VEGFR-TKI) now set as the standard front-line treatment for advanced renal cell carcinoma (RCC). However, the roles of VEGFR-TKIs and IOs in the neoadjuvant setting for locoregional/locally advanced RCC remain undefined, where the goals may be primary tumor downsizing/downstaging and potentially eradicating micrometastatic disease. This review will examine VEGFR-TKI monotherapy, IO monotherapy, and VEGFR-TKI/IO combination regimens in a preoperative setting with a focus on the efficacy, toxicity, surgical, and long-term implications. Full article
(This article belongs to the Special Issue Immune Landscape of Renal Cell Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop